BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

  Hansa Biopharma AB, (“Hansa” or the “Company”) (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete.

  May 31, 2024

   · 

  8 min read
• Pharm Country

  Quantum-Si Announces Presentations at ASMS and ESHG

  Quantum-Si Incorporated today announced presentations at two upcoming industry conferences.

  May 31, 2024

   · 

  2 min read
• Biotech Beach

  Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO

  Agendia ® , Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens.

  May 31, 2024

   · 

  5 min read
• Biotech Beach

  MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting

  MBrace™ Therapeutics, Inc. today announced that the Company will be presenting a Trial in Progress (TIP) poster at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31-June 4, 2024, in Chicago, Illinois.

  May 31, 2024

   · 

  3 min read
• Drug Development

  EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

  May 31, 2024

   · 

  18 min read
• Biotech Bay

  Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

  Mirum Pharmaceuticals, Inc. has adopted a positive opinion of LIVMARLI® (maralixibat) oral solution for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older.

  May 31, 2024

   · 

  8 min read
• Female Infertility Market to Reach US$ 2.7 Billion by 2034, Impelled by Continual Technological Advancements

  Analysts at IMARC expect the global female infertility market to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

  May 31, 2024

   · 

  9 min read
• Deals

  AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share.

  May 31, 2024

   · 

  4 min read
• Genetown

  nference to Present AI-Driven Research at 2024 ASCO Annual Meeting

  nference will present research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago.

  May 31, 2024

   · 

  3 min read